$50M CEO Buy Against Unanimous Selling Signals
Co-CEO Robert Duggan just dropped nearly $50 million on Summit Therapeutics at $13.12 per share. Every technical timeframe is flashing sell, RSI sits at 35, and momentum shows clear headwinds. But Duggan's track record on this name tells a different story. Insiders here have generated 41% average returns at the 90-day mark, even when the entry looked terrible.
The Filing
| Ticker | SMMT |
| Company | Summit Therapeutics Inc. |
| Insider | Robert Duggan, Co-Chief Executive Officer |
| Buy amount | $50.0M |
| Filing date | June 12, 2026 |
| Conviction | Favorable · 67/100 |
| Setup type | Contrarian Setup |
Ultimate members received this analysis in real time.